Icagen, Pfizer Inc, Yale University deal

The parties will collaborate to evaluate in vitro compounds targeting sodium ion channel Nav1.7 (SCN9A) to treat erythromelalgia, a rare genetic disorder characterized by burning pain, and warmth and...